Author

Country

Inclusion period

Study type

Histology

(SCC/ AC/ Other)

Tumor location

(Cervical/ Upper/ Mid/ Lower/ Junction)

stage

sample size (SD/HD)

radiation dose

radiation technique

Concurrent chemotherapy

Adjuvant chemotherapy

Follow-up time (median, range)

3-year OS rate

(SD/HD)

Zhu et al. [25]

China

2007.01-2007.12

RCT

44/0/0

44 (cervical and upper)

II-III⁺

44

(24/20)

60 Gy/30 Fx

63.9 Gy/30 Fx

sIMRT

PF × 2

PF × 2

36 m, -

25.0%/ 35.0%

Ma et al. [23]

China

2005.05-2010.12

NRCT

112/0/0

0/21/79/ 12/0

T2-4, N0-1, M0^#

112

(60/52)

50.4 Gy/28 Fx

66 (63-70) Gy

IMRT

PF/3 weeks

-

18 m, 5 - 40 m

0/ 21.3%

Nayan et al. [24]

India

not reported

RCT

28/0/0

0/4/24/0/0

II-III⁺⁺

28

(14/14)

50.4 Gy/28 Fx

64.8 Gy/36 Fx

3D-RT and IMRT

PF × 2

-

21 m, 18 - 26 m

-

Crehange et al. [22]

France

2011.06-2019.10

RCT II/III

191/25/1

unknown

I-III⁺⁺

217

(109/ 108)

50.0 Gy/25 Fx

66.0 Gy/33 Fx

3D-RT and IMRT

FOLFOX-4 × 3

FOLFOX-4 × 3

35.4 m, 1.3 - 65.7 m

-

You et al. [18]

China

2016.04-2019.04

RCT III

144/0/0

144 (thoracic)

T1-4 N0-1 M0-1a^+##

144

(73/71)

50.4 Gy/28 Fx

59.4 Gy/33 Fx

IMRT

TC × 6

TC × 2 (max)

36 m, -

38.1%/ 43.5%

Hulshof et al. [20]

Dutch

2012.09-2018.06

RCT III

159/95/6

13/60/67/ 100/17

II-IVA⁺⁺

260

(130/ 130)

50.4 Gy/28 Fx

61.6 Gy/28 Fx

IMRT

TC × 6

-

50 m, -

42.0%/ 39.0%

Xu et al. [19]

China

2013.05-2017.05

RCT III

319/0/0

185 (cervical and upper)

134 (middle and lower)

IIA-IVA⁺

319

(160/ 159)

50.0 Gy/25 Fx

60.0 Gy/30 Fx

IMRT and IGRT

DP/week

DP × 2

34 m, -

53.1%/ 52.7%